Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea
Clearmind Medicine (NASDAQ: CMND) has secured a patent publication in South Korea for its innovative combination therapy using MEAI and N-Acylethanolamines to treat cocaine addiction. The patent is based on successful preclinical trials conducted at Bar-Ilan University's Gonda Multidisciplinary Brain Research Center in Israel.
The research demonstrated that animals treated with MEAI showed significant reduction in cocaine-induced cravings while maintaining normal responses to natural rewards like sucrose. This suggests MEAI specifically targets drug-related compulsions without affecting the general reward system.
The development is part of Clearmind's collaboration with SciSparc (NASDAQ: SPRC), combining Clearmind's MEAI psychedelic treatment with SciSparc's PEA for addiction and mental health applications. Multiple patent applications have been filed in the U.S. and other global jurisdictions.
Clearmind Medicine (NASDAQ: CMND) ha ottenuto la pubblicazione di un brevetto in Corea del Sud per la sua innovativa terapia combinata che utilizza MEAI e N-Acilethanolamine per trattare la dipendenza da cocaina. Il brevetto si basa su trial preclinici di successo condotti presso il Gonda Multidisciplinary Brain Research Center dell'Università Bar-Ilan in Israele.
La ricerca ha dimostrato che gli animali trattati con MEAI hanno mostrato una significativa riduzione dei desideri indotti dalla cocaina, mantenendo al contempo risposte normali a ricompense naturali come il saccarosio. Ciò suggerisce che MEAI colpisce specificamente le compulsioni legate alla droga senza influenzare il sistema di ricompensa generale.
Lo sviluppo fa parte della collaborazione di Clearmind con SciSparc (NASDAQ: SPRC), combinando il trattamento psichedelico MEAI di Clearmind con il PEA di SciSparc per applicazioni relative alla dipendenza e alla salute mentale. Sono state presentate numerose domande di brevetto negli Stati Uniti e in altre giurisdizioni globali.
Clearmind Medicine (NASDAQ: CMND) ha asegurado la publicación de una patente en Corea del Sur para su innovadora terapia combinada que utiliza MEAI y N-Acilethanolaminas para tratar la adicción a la cocaína. La patente se basa en ensayos preclínicos exitosos realizados en el Centro de Investigación Cerebral Multidisciplinario Gonda de la Universidad Bar-Ilan en Israel.
La investigación demostró que los animales tratados con MEAI mostraron una reducción significativa de los antojos inducidos por la cocaína mientras mantenían respuestas normales a recompensas naturales como la sacarosa. Esto sugiere que MEAI se dirige específicamente a las compulsiones relacionadas con las drogas sin afectar el sistema de recompensa general.
El desarrollo es parte de la colaboración de Clearmind con SciSparc (NASDAQ: SPRC), combinando el tratamiento psicodélico MEAI de Clearmind con el PEA de SciSparc para aplicaciones de adicción y salud mental. Se han presentado múltiples solicitudes de patente en EE. UU. y otras jurisdicciones globales.
클리어마인드 메디슨 (NASDAQ: CMND)는 MEAI와 N-아실에탄올아민을 사용하여 코카인 중독을 치료하는 혁신적인 복합 요법에 대한 특허 출원을 한국에서 확보했습니다. 이 특허는 이스라엘 바르일란 대학교의 곤다 다학제 뇌 연구 센터에서 수행된 성공적인 전임상 시험을 기반으로 하고 있습니다.
연구 결과, MEAI로 치료받은 동물들은 코카인으로 유도된 갈망이 상당히 감소했으며, 자당과 같은 자연 보상에 대한 정상적인 반응을 유지했습니다. 이는 MEAI가 일반적인 보상 시스템에 영향을 미치지 않고 약물 관련 강박증을 특정적으로 겨냥한다는 것을 시사합니다.
이 개발은 사이 스파크 (NASDAQ: SPRC)와의 클리어마인드의 협력의 일환으로, 클리어마인드의 MEAI 환각 치료와 사이 스파크의 PEA를 결합하여 중독 및 정신 건강 응용 프로그램에 활용되고 있습니다. 미국 및 기타 글로벌 관할권에 여러 개의 특허 신청이 제출되었습니다.
Clearmind Medicine (NASDAQ: CMND) a obtenu la publication d'un brevet en Corée du Sud pour sa thérapie combinée innovante utilisant MEAI et N-Acylethanolamines pour traiter la dépendance à la cocaïne. Le brevet est basé sur des essais précliniques réussis réalisés au Gonda Multidisciplinary Brain Research Center de l'Université Bar-Ilan en Israël.
La recherche a démontré que les animaux traités avec MEAI ont montré une réduction significative des envies induites par la cocaïne, tout en maintenant des réponses normales aux récompenses naturelles comme le saccharose. Cela suggère que MEAI cible spécifiquement les compulsions liées aux drogues sans affecter le système de récompense général.
Ce développement fait partie de la collaboration de Clearmind avec SciSparc (NASDAQ: SPRC), combinant le traitement psychédélique MEAI de Clearmind avec le PEA de SciSparc pour des applications en matière de dépendance et de santé mentale. Plusieurs demandes de brevet ont été déposées aux États-Unis et dans d'autres juridictions mondiales.
Clearmind Medicine (NASDAQ: CMND) hat in Südkorea die Veröffentlichung eines Patents für seine innovative Kombinationstherapie mit MEAI und N-Acylethanolaminen zur Behandlung von Kokainabhängigkeit gesichert. Das Patent basiert auf erfolgreichen präklinischen Studien, die am Gonda Multidisciplinary Brain Research Center der Bar-Ilan-Universität in Israel durchgeführt wurden.
Die Forschung zeigte, dass Tiere, die mit MEAI behandelt wurden, eine signifikante Reduktion von kokainbedingten Gelüsten aufwiesen, während sie normale Reaktionen auf natürliche Belohnungen wie Saccharose beibehielten. Dies deutet darauf hin, dass MEAI gezielt drogenbedingte Zwänge anspricht, ohne das allgemeine Belohnungssystem zu beeinträchtigen.
Die Entwicklung ist Teil der Zusammenarbeit von Clearmind mit SciSparc (NASDAQ: SPRC), wobei Clearminds MEAI-psychedelische Behandlung mit SciSparcs PEA für Anwendungen in den Bereichen Sucht und psychische Gesundheit kombiniert wird. Mehrere Patentanmeldungen wurden in den USA und anderen globalen Jurisdiktionen eingereicht.
- Patent secured in South Korea for cocaine addiction treatment
- Successful preclinical trial results showing reduced cocaine cravings
- Strategic collaboration with SciSparc (NASDAQ: SPRC)
- Multiple patent applications filed globally
- Treatment still in preclinical stage, requiring further clinical trials
- No revenue generation from the treatment yet
Vancouver, Canada, March 10, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of a patent by the Korean Intellectual Property Office (KIPO), South Korea’s official patent and intellectual property authority. The patent covers the Company’s innovative combination therapy of MEAI and N-Acylethanolamines for the treatment of cocaine addiction.
The patent is based on preclinical trial results led by Professor Gal Yadid and his team at the Gonda Multidisciplinary Brain Research Center at Bar-Ilan University in Israel. These studies build upon earlier experiments in which animals treated with MEAI exhibited a significant reduction in cocaine-induced cravings.
Further research was conducted in rats to assess whether MEAI’s effects on drug-seeking behavior extended to natural rewards, given that reward-based reinforcement is a fundamental survival mechanism across species. The study produced positive results, demonstrating that while MEAI reduced cocaine-seeking behavior, it did not impair the rats’ response to natural rewards such as sucrose. This finding suggests that MEAI’s impact on drug cravings is not tied to the general reward system but is specifically targeted at drug-related compulsions.
This pioneering research has led to multiple patent applications in the U.S. and other global jurisdictions and is part of Clearmind’s ongoing collaboration with SciSparc Ltd. (NASDAQ: SPRC) ("SciSparc"), a specialty clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders. The collaboration aims to combine Clearmind's MEAI, a novel proprietary psychedelic treatment for addiction and mental health, with SciSparc's PEA.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
About SciSparc Ltd.
SciSparc Ltd. (SPRC) is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; and SCI-210 for the treatment of autism and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds’ oil-based products on the Amazon.com Marketplace.
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2023 filed with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ
What did Clearmind Medicine's (CMND) recent patent in South Korea cover?
What were the key findings of CMND's preclinical trials for cocaine addiction treatment?
How is Clearmind Medicine (CMND) collaborating with SciSparc in addiction treatment?
Where else has Clearmind Medicine (CMND) filed patent applications for their cocaine addiction treatment?
